

NUTRAPLUS INDIA LIMITED  
COMPANY'S CODE : 24764

STATEMENT OF UNAUDITED FINANCIAL RESULT FOR THE QUARTER AND HALF YEAR ENDED ON SEPTEMBER 30, 2015

Particulars	Quarter Ended on			Half Year ended		Financial Year Ended
	30.09.15	30.06.15	30.09.14	30.09.15	30.09.14	31.03.15
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. Net Sales	1,924.88	1,527.91	1,267.90	3,452.79	3,013.56	6,504.31
2. Expenses						
a) (Increase)/ Decrease in Stock	55.97	(291.05)	96.78	(347.01)	246.82	(170.77)
b) Consumption of Raw Materials	1,310.06	1,099.86	1,348.02	2,409.92	2,493.16	4,891.21
c) Purchase of Trade Goods	-	-	-	-	-	-
d) Staff Costs (Refer Note No. 6)	39.23	76.71	91.67	115.94	129.13	295.50
e) Depreciation	56.65	37.24	10.98	93.89	62.80	140.03
f) Other Expenditure	280.62	366.09	291.51	646.71	452.51	1,168.56
<b>Total Expenses</b>	<b>1,630.58</b>	<b>1,288.86</b>	<b>1,838.96</b>	<b>2,919.44</b>	<b>3,384.22</b>	<b>6,324.53</b>
3. Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	294.30	239.05	(571.05)	533.35	(370.65)	179.78
4. Other Income	21.80	1.72	1.00	23.52	4.80	20.33
5. Profit Before Interest and Exceptional Items (3+4)	316.10	240.78	(570.05)	556.87	(365.85)	200.11
6. Interest	140.55	52.31	113.56	192.86	187.18	451.56
7. Profit after Interest but before Exceptional Items (5-6)	175.55	188.47	(683.61)	364.02	(553.03)	(251.45)
8. Exceptional Items	-	-	2,325.61	-	2,325.61	-
9. Profit/(Loss) from Ordinary Activities Before Tax (7-8)	175.55	188.47	(3,009.22)	364.02	(2,878.64)	(251.45)
10. Tax Expense	15.00	38.85	-	53.85	28.00	(159.30)
11. Net Profit / (Loss) from Ordinary Activities after Tax (9-10)	160.55	149.62	(3,009.22)	310.17	(2,906.64)	(92.15)
12. Extraordinary Items (Refer note no. 5)	(13.56)	1.15	-	(12.41)	-	313.90
13. Net Profit / (Loss) for the period (11-12)	146.99	150.77	(3,009.22)	297.76	(2,906.64)	(406.05)
14. Paid up Equity Capital (Face Value of Rs.10/- each)	1,196.33	1,196.33	588.50	1,196.33	588.50	1,116.33
15. Reserves excluding revaluation reserves per balance sheet of previous accounting year	-	-	-	-	-	3,059.28
16. Earning per Share (EPS)						
a. Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	1.23	1.26	(51.05)	2.49	(49.31)	(6.21)
b. Basic and diluted EPS AFTER Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	1.23	1.26	(51.05)	2.49	(49.31)	(1.41)
17. Public Shareholding						
Number of Shares	7,253,348	7,253,348	2,687,500	7,253,348	2,687,500	7,255,848
% of Shareholding	60.63	60.63	45.59	60.63	45.59	65.00
18. Promoter and Promoter Group Shareholding						
a. Pledged/ Encumbered						
- Number Of Shares	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of Shares as percentage of total Shareholding of Promoters and Promoter Group	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of Shares as percentage of total share capital of the Company	NIL	NIL	NIL	NIL	NIL	NIL
b. Non Encumbered						
- Number Of Shares	4,710,000	4,710,000	3,207,500	4,710,000	3,207,500	3,907,500
- Percentage of Shares as percentage of total Shareholding of Promoters and Promoter Group	100	100	100	100	100	100
- Percentage of Shares as percentage of total share capital of the Company	39.37	39.37	54.41	39.37	54.41	35.00

**Statement of Assets and Liabilities as at 30 th September 2015**


Particulars	30.09.2015	31.03.2015
	In Lacs (Unaudited)	In Lacs (Audited)
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholders' funds</b>		
(a) Share capital	1,196.33	1,116.33
(b) Reserves and surplus	3,206.16	3,059.28
(c) Money received against share warrants	516.38	542.08
(d) Money received against share application	-	-
	4,918.87	4,717.69
Share application money pending allotment	-	-
<b>Non-current liabilities</b>		
(a) Long-term borrowings	3,336.61	1,550.46
(b) Deferred tax liabilities (net)	148.61	148.61
(c) Long-term provisions	25.94	25.94
	3,511.16	1,725.01
<b>Current liabilities</b>		
(a) Short-term borrowings	2,532.43	2,014.73
(b) Trade payables	1,911.95	2,420.39
(c) Other current liabilities	524.07	485.37
(d) Short-term provisions	133.09	43.50
	5,101.54	4,963.98
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>13,531.57</b>	<b>11,406.68</b>

<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Fixed assets		
(i) Tangible assets	2,470.83	2,229.76
(ii) Intangible Assets	49.26	65.68
(ii) Capital work-in-progress	3,195.32	1,341.90
	5,715.41	3,637.34
(b) Non-current investments	5.33	5.33
(c) Other Non-Current Assets	5.80	169.84
	5,726.54	3,812.51
<b>Current assets</b>		
(a) Current Investments	415.00	415.00
(b) Inventories	2,120.46	1,737.85
(c) Trade receivables	1,948.04	1,337.91
(d) Cash and cash equivalents	120.87	1,137.11
(e) Short-term loans and advances	619.14	384.78
(f) Other Current Assets	2,581.53	2,581.53
	7,805.03	7,594.17
<b>TOTAL ASSETS</b>	<b>13,531.57</b>	<b>11,406.68</b>

**Notes :**

- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their Meeting held on November 10, 2015.
- The results for the quarter and half year ended 30 September 2015 have been subjected to a "Limited review" by the Statutory Auditors of the company. An unqualified review report has been issued by them thereon.
- Insurance claim for fire occurred at one of our factory premises in August, 2014 is still under process.
- The partial restart of the production at the said factory has commenced on October 10, 2015
- The expenditures for the quarter are on account reversal of excise on stock loss by fire & expenditures on the site clearance.
- Staff costs for the quarter is net off Rs. 23.22 lacs pertaining to the previous quarter rectified on account of the capitalization to conform to the accounting principles.
- Deferred tax will be calculated at the end of the year.
- The Company operates only in one segment viz, Bulk drugs and their intermediate products, hence there are no other reportable segments as per the Accounting Standard 17.
- There was one investor complaint received and was solved during the quarter ended September, 2015.
- Previous period /year figures have been regroup / rearranged wherever necessary to conform to the current period / year presentation.

**By order of the Board  
For NUTRAPLUS INDIA LIMITED.**

  
**Mukesh Naik**  
**Managing Director**

**Place : Mumbai**  
**Dated : 10th November, 2015**

# AMPAC & ASSOCIATES

Chartered Accountants

D-102, Green Lawn Apartment, Opp. St. Pius College,  
Aarey Road, Goregaon (East), Mumbai 400 063  
Phone Nos.022 2927 0099, 2927 0104

To,  
The Board of Directors,  
NUTRAPLUS INDIA LIMITED

## LIMITED REVIEW REPORT FOR THE THREE MONTHS PERIOD ENDED 30th September' 2015

1. We have reviewed the accompanying statement of unaudited standalone results of NUTRAPLUS INDIA LIMITED, ('the Company) for the Quarter and Half Year ended 30th September' 2015 ('the Statement), being submitted by the Company pursuant to the requirement of clause 41 of Listing Agreement with the stock Exchanges, except for the disclosures regarding 'Public Shareholding' and Promoter and Promoter Group Shareholding' Which have been traced from disclosure made by the management and have not been reviewed by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our limited review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in items of clause 41 of the listing agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR AMPAC & ASSOCIATES  
Chartered Accountants  
(FRN 112236w)

Mumbai  
Dated: November 10, 2015



*Milani Desai*  
Milan Desai  
Partner  
M. No. 042769